FFO
GALT icon

Fortitude Family Office’s Galectin Therapeutics GALT Stock Holding History

Fortitude Family Office’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73K Buy
+372
New +$964 ﹤0.01% 1533
2026
Q1 		– Sell
-90
Closed -$374 – 1960
2025
Q4 		$374 Buy
+90
New +$474 ﹤0.01% 1784

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fortitude Family Office's GALT Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 372 shares worth $1.73K. The stake represents ﹤0.01% of the portfolio and ranks #1533 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in GALT as recently as Q4 2025.

Fortitude Family Office first reported a position in GALT in Q4 2025 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Fortitude Family Office held 372 shares of Galectin Therapeutics worth $1.73K as of Q2 2026.
  • Galectin Therapeutics was a new Fortitude Family Office position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1533 holding.
  • Fortitude Family Office first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.